In patients with locally advanced or metastatic ER‐positive/HER2‐negative breast cancer, ET with either aromatase inhibitors (AI) or fulvestrant plus a cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor is recommended as first‐line standard of care (SOC). Here, CDK4 is linked to breast cancer.